Table 3. Prognostic value of clinicopatholgic factors and candidate biomarkers.
| Characters | Univariate analyisis | Multivariate analyisis | |||
|---|---|---|---|---|---|
| 5-year survival rate | P* | HR | 95%CI | P# | |
| Gender | |||||
| Male | 37.4 | 0.065 | |||
| Female | 58.6 | ||||
| Age | |||||
| < 60 | 49.6 | 0.666 | |||
| ≥ 60 | 45.3 | ||||
| Tumor diameter (cm) | |||||
| ≤ 5 | 41.8 | 0.862 | |||
| > 5 | 49.6 | ||||
| Differentiation | |||||
| Well + Moderate | 57.7 | 0.124 | |||
| Poor | 34.1 | ||||
| Tumor invasion | |||||
| T1 + T2 | 58.6 | 0.015 | 1 | ||
| T3 + T4 | 37.9 | 1.97 | 0.92–4.19 | 0.079 | |
| Lymph node invasion | |||||
| No (N0) | 80 | P < 0.001 | 1 | ||
| Yes (N1/2/3) | 6.9 | 15.6 | 5.42–45.3 | P < 0.001 | |
| Distant metastasis | |||||
| M0 | 49.6 | P < 0.001 | 1 | ||
| M1 | 0 | 4.15 | 1.55–11.1 | 0.005 | |
| TNM stage | |||||
| I | 75 | P < 0.001 | |||
| II | 57.6 | ||||
| III | 38.6 | ||||
| IV | 0 | ||||
| Lauren subtype | |||||
| Intestinal | 59 | 0.009 | |||
| Diffuse | 24 | ||||
| Mixed | 32.6 | ||||
| Peritoneal dissemination | |||||
| Yes | 0 | 0.007 | |||
| No | 47.6 | ||||
| FGFR2 | |||||
| low | 52.2 | 0.031 | 1 | ||
| high | 35.9 | 1.22 | 0.65–2.26 | 0.537 | |
| SPRY1 | |||||
| low | 46.8 | 0.577 | |||
| high | 46.8 | ||||
| SPRY2 | |||||
| low | 43.2 | 0.020 | 1 | ||
| high | 61.3 | 0.61 | 0.28–1.33 | 0.216 | |
| SPRY3 | |||||
| low | 47.1 | 0.737 | |||
| high | 0 | ||||
| SPRY4 | |||||
| low | 48.2 | 0.947 | |||
| high | 39.5 | ||||
*
means calculated by log-rank test, #means calculated by Cox-regression hazard model,
Abbreviations: FGFR2 = fibroblast growth factor receptor 2, SPRY = sprouty, HR = hazard ratio, CI = confidence internal.